This is an open label, Phase 1/2, first-in-human, multiple ascending dose, and dose-expansion study of IDP-023 administered as a single agent and in combinatio…

NHLMultiple MyelomaBlood Cancer+4 more

~Estimated

~$10 – $8,750

Indapta Therapeutics, INC.NCT06119685

Phase 2

A Phase II Study of the Combination of Pembrolizumab and All-Trans Retinoic Acid Combination Treatment of Relapsed Hodgkin Lymphoma (HL) and B-Non-Hodgkin- Lymphoma (B-NHL)

This is a Phase II single-center open label trial of the combination of ATRA and pembrolizumab treatment in patients with histologically proven, relapsed or re…

Relapsed Hodgkin LymphomaRefractory Hodgkin LymphomaRelapsed Non-Hodgkin Lymphoma+2 more

A Phase I Study of Bivalent CD79b and CD19 Directed CAR T Cells in Patients With Relapsed/Refractory Non-Hodgkin Lymphoma

This research study involves the study of CD79b-19 CAR T cells for treating people with relapsed/refractory Non-Hodgkin Lymphoma and to understand the side eff…

Non-hodgkin LymphomaRelapsed Non-Hodgkin LymphomaRefractory Non-Hodgkin Lymphoma+7 more

~Estimated

~$10 – $7,500

Marcela V. Maus, M.D.,Ph.D.NCT06026319

Phase 1

A Phase 1, Open-label, Multi-center, Dose Escalation Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Anti-tumor Activity of HCB101 in Subjects With Advanced Solid Tumors or Relapsed and Refractory Non-Hodgkin Lymphoma

The purpose of this study is to find out whether IV injection of HCB101 is an effective treatment for different types of advanced solid tumors or relapsed and …

Advanced Solid TumorRefractory Non-Hodgkin Lymphoma

~Estimated

~$10 – $8,750

FBD Biologics LimitedNCT05892718

← PreviousPage 2 of 2Next →